Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Alone or With Entinostat in Muscle-Invasive Bladder Cancer
NCT03978624Phase 2Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Sep 2020
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and entinostat in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Changes in CD8 T Cell Immune Gene Signature at 10 weeks. Started Sep 2020; status: active, not recruiting.
02
Drugs
pembrolizumabentinostat
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03978624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978624.